Optimizing antibiotic use in MSSA bacteremia: a stewardship-focused approach

Antimicrobial stewardship is essential for optimizing therapy in bloodstream infections. Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia requires prompt beta-lactam treatment, and delays in transitioning from empirical anti-MRSA therapy can result in adverse outcomes. Rapid diagnostics like the BioFire Blood Culture Identification (BCID) PCR panel, combined with stewardship interventions, significantly improve care by reducing unnecessary broad-spectrum antimicrobial use. A study by Yetukuri et al. demonstrated that integrating BCID with stewardship efforts reduced time to optimal therapy by 20 h (49 vs 29.1 h, P < 0.001) and shortened both bacteremia duration and anti-MRSA therapy without affecting mortality or hospital stay. These findings emphasize that stewardship programs, including real-time reviews and prescriptive guidance, are critical for translating rapid diagnostic results into timely, targeted treatment. Leveraging stewardship with advanced diagnostics offers a strategic approach to enhancing outcomes and combating antimicrobial resistance.